Early cardiovascular risk factors in South Asians
|
|
- Jessie O’Brien’
- 6 years ago
- Views:
Transcription
1 Early cardiovascular risk factors in South Asians MINTU TURAKHIA, MD MAS Instructor of Medicine, Stanford University Director of Cardiac Electrophysiology, Palo Alto VA Research Chair, South Asian Heart Center Disclosures! Research support:! VA HSR&D Career Development Award! AHA National Scientist Development Grant! VA MERIT Award IIR04-248! El Camino Hospital Foundation! No other financial disclosures 2 Objectives! Scope and burden of CVD in South Asians! Screening and risk assessment program at SAHC! SAHC clinical findings! Future avenues for research Case! 33-year old nonsmoking engineer presents with chest pain, anterior ST elevation, tachycardia, and rales! Angiography demonstrated 3-vessel disease with proximal LAD occlusion! EF 40%! Total cholesterol 234, LDL 156, HDL 32, triglycerides 45! BMI 25 kg/m 2! Fasting blood sugar:
2 South Asia = Indian subcontinent! India, Pakistan, Sri Lanka, Bangladesh! 20% of global population! 2.5 million on United States! Heterogeneous (language, diet, culture, lifestyle) Epidemiology! South Asians have a four-fold higher risk of MI and cardiovascular death compared to Caucasians International prevalence of CV disease (SHARE study, Lancet 2000)! South Asians: 10.7%! Europeans 5.4%! Chinese 2.4% 5 6 CHD mortality in India M M M M M By 2010, India will bear % of the 1461 world s 1108 CAD burden (# in thousands) Men Women Total Ghaffar et al. BMJ 2004; 328: Epidemiology! Younger! Prone to have MI at earlier age (< 40 years in men)! 25% of MIs before age 40; 33% before age 45! Three-fold higher risk of second MI compared to Caucasians! Sicker! Anterior infarction! More left main and multivessel disease at time of cath! Present later in the course! Higher post-mi mortality! Younger at first heart failure hospitalization! Die earlier! Traditional risk factors do not entirely account for this discrepancy 7 8
3 Why are South Asians at high risk?! Three possibilities 1. Excess burden of conventional risk factors 2. Greater susceptibility to similar burden of risk factors 3. Unrecognized ( emerging ) risk factors! May be genetic, environmental, or both Framingham Risk Factors! Smoking! Hypertension! High total cholesterol or LDL! Low HDL! Diabetes Mellitus! Age! Gender 9 10 Prevalence of Framingham risk Framingham Offspring Study Asian Indians 10-year risk of 33-year old male with anterior MI and 3VD: 1 percent Smoking HTN LDL > 160 TG > 250 (Enas, Indian Heart J, 1996) Risk Factors for Early Myocardial Infarction in South Asians Compared With Individuals in Other Countries Joshi, et al with Yusuf (JAMA 2007) Context South Asians have high rates of acute myocardial infarction (AMI) at younger ages compared with individuals from other countries but the reasons for this are unclear. Objective To evaluate the association of risk factors for AMI in native South Asians, especially at younger ages, compared with individuals from other countries. Design, Setting, and Participants Standardized case-control study of 1732 cases with first AMI and 2204 controls matched by age and sex from 15 medical centers in 5 South Asian countries and cases and controls from other countries. Individuals were recruited to the study between February 1999 and March Main Outcome Measure Association of risk factors for AMI. Results The mean (SD) age for first AMI was lower in South Asian countries (53.0 [11.4] years) than in other countries (58.8 [12.2] years; P.001). Protective factors were lower in South Asian controls than in controls from other countries (moderate- or high-intensity exercise, 6.1% vs 21.6%; daily intake of fruits and vegetables, 26.5% vs 45.2%; alcohol consumption once/wk, 10.7% vs 26.9%). However, some harmful factors were more common in native South Asians than in individuals from other countries (elevated apolipoproteinb100/apolipoproteina-iratio,43.8%vs31.8%;historyofdiabetes,9.5%vs7.2%). Similar relative associations were found in South Asians compared with individuals from other countries for the risk factors of current and former smoking, apolipoprotein B100/ apolipoprotein A-I ratio for the top vs lowest tertile, waist-to-hip ratio for the top vs lowest tertile, history of hypertension, history of diabetes, psychosocial factors such as depression and stress at work or home, regular moderate- or high-intensity exercise, and daily intake of fruits and vegetables. Alcohol consumption was not found to be a risk factor for AMI in SouthAsians.Thecombinedoddsratioforall9riskfactorswassimilarinSouthAsians(123.3; 95% confidence interval [CI], ] and in individuals from other countries (125.7; 95% CI, ). The similarities in the odds ratios for the risk factors explained a high and similar degree of population attributable risk in both groups (85.8% [95% CI, 78.0%- 93.7%] vs 88.2% [95% CI, 86.3%-89.9%], respectively). When stratified by age, South Asians had more risk factors at ages younger than 60 years. After adjusting for all 9 risk factors, the predictive probability of classifying an AMI case as being younger than 40 years was similar in individuals from South Asian countries and those from other countries. Conclusion The earlier age of AMI in South Asians can be largely explained by higher risk factor levels at younger ages. JAMA. 2007;297: Author Affiliations: Department of Medicine, Gov- sity, Karachi, Pakistan (Dr Kazmi); Nepal Hyperten-! International case-control study; includes 5 South Asian countries! Cases: 1700 pts of South Asian origin after first MI! Controls:! Non South Asian with MI! South Asians without MI 11
4 Interheart study! Protective factors lower in South Asians! Exercise 6% v. 21%! Daily fruits and vegetables 26% v. 45%! Alcohol!"once/week 11% v. 27%! Some harmful factors more common! Diabetes 10% v. 7%! High ApoB100 /Apo A-I (LDL:HDL) ratio 44% v. 32%! Lower mean age of MI (53 vs 59 yrs)! Higher levels of risk factors at younger age (< 60 and < 40)! 9 conventional risk factors accounted for 86% of population-attributable risk of early MI Limitations! Few South Asian subjects drawn from Europe or North America! 14% unmeasured attributable risk in model; could misclassify 1 out of 6 South Asians! Possible added prognostic value of lipid subparticles, insulin resistance, and additional biomarkers! Epidemiology in United States not well characterized Hospitalization Rates for CAD in California PMR = % of deaths from CAD in ethnic group % of deaths from CAD in whole population Likelihood of hospitalization (vs. White) White Asian Indian Chinese Japanese Filipino (Palaniappan, L, Ann Epid 2004) (Palaniappan, L, Ann Epid 2004) 15 16
5 Prevalence of Diabetes Mellitus and Related Conditions in Asian Indians Living in the United States Rajesh Venkataraman, MD, MPH, Navin C. Nanda, MD, Gurpreet Baweja, MD, Naresh Parikh, MD, and Vishal Bhatia, MD Prevalence of Diabetes Mellitus and Related Conditions in Asian Indians Living in the United States Rajesh Venkataraman, MD, MPH, Navin C. Nanda, MD, Gurpreet Baweja, MD, Naresh Parikh, MD, and Vishal Bhatia, MD TABLE 1 Baseline Characteristics of Participants Characteristics Total (n 1,046) Diabetics (n 192) Nondiabetics (n 854) Men 51% 62.5% 51% Women 49% 37.5% 49% Mean age (yrs)* Mean body mass index (kg/m 2 )* Hypertension 23.7% 45.2% 18.9% Hypercholesterolemia 18.5% 27.3% 16.4% Myocardial infarction 6.5% 16.3% 4.3% Coronary artery intervention 10.7% 21% 8.4% History of dialysis 2.7% 8.4% 1.4% Stroke 2.9% 5.2% 2.2% Family history of diabetes mellitus 22.7% 53.1% 14% *Figures are mean SD. p 0.001, independent sample t test between diabetic and nondiabetic groups. p 0.05, independent sample t test between diabetic and nondiabetic groups. (Venkataraman, Am J Cardiol 2004) (Venkataraman, Am J Cardiol 2004) 17 Where is the unmet need?! More South Asians have CAD & present at an earlier age! Conventional risk factors, novel risk factors, or both?! Treated or untreated?! When does it start?! Role of socioeconomic status and access to care?! Where are the high-risk people? How can we get to them? Barriers to care! Lack of physician awareness of need for early screening and aggressive treatment in South Asians! Patients don t know to ask! No focused resource center for clients and physicians! 2005: Creation of South Asian Heart Center 19 20
6 The mission of the South Asian Heart Center is to reduce the high incidence of coronary disease among South Asians through a comprehensive, culturallyappropriate program incorporating education, advanced screening, lifestyle changes, and case management. Prevention Program Methodology! Easy sign-up at website for advanced screening! ASSESSMENT: Guided heart-heath risk assessment Advanced lab Brief physical exam! IDENTIFICATION: Detailed risk & risk factor stratification! MANAGEMENT: Customized risk-factor mgmt. plan & followthrough Results consultation with nurse practitioner Nutrition consultations with registered dietician Frequent follow-up over 1 year with heart health coaches Retest tracking, facilitation, communicating results Metabolic Evaluation Metabolic Syndrome & Risk Marker Evaluation 23 24
7 SAHC evaluation process! Sign up online! minute risk assessment by phone! Lab tests (12-hour fasting)! min appointment to discuss results and recommendations (not prescription)! Medication, exercise, diet, stress reduction! Sent back to referring MD for interventions (MD ed all reports and recommendations as well)! Nutrition appointment! Follow-up! Did you see your doctor?! Are you doing the things that were recommended? SAHC Experience: Bay Area South Asian Study! Started initial health screenings starting in 2006! 1 year ago: 800 participants! December 2008: 2100 participants! > 3500 patient encounters! Anthropomorphic, demographic, and medical information collected! Fasting blood specimen collected for cholesterol and metabolic profile screening! DNA banked for a sub-cohort that consented Research aims! Define prevalence of metabolic syndrome and its components in cohort! Define burden of CV risk factors and metabolic syndrome in youngest participants SAHC MetS study! From Jan 2006-Dec 2008: 1445 completed screening program including laboratory testing! Lab testing: Berkeley Heart Lab panel! Fasting lipids! Glucose! Lipid subfractions! Inflammatory markers! Plasma insulin (E Flowers, in press, 2010) 27 28
8 Metabolic Syndrome (NCEP ATP III) Any 3 of the 5 Abdominal obesity > 102 cm for males and >88 cm for women Elevated Triglycerides >150 mg/dl Low HDL cholesterol (<40 mg/dl for men, <50 mg/dl for women) Elevated Blood Pressure (>130/85 mm Hg) Elevated fasting glucose (>110 mg/dl) Shown to markedly underestimate prevalence of Metabolic Syndrome Metabolic Syndrome (IDF) Waist Circumference (> 90 cm for men, >80 cm for women) + Any two of following Elevated Fasting Glucose >100 mg/dl Elevated Triglycerides (> 150 mg/dl) Elevated Blood Pressure ( > 130/85 mm Hg) Low HDL (<40 for men, <50 for women) Characteristics Mean ± SD or n (%) Men (n = 1012) Women (n = 433) p-value Age (years) 43 ±10 43 ±10 43 ± Birth country (n = 849) South Asia 763 (89) 526 (90) 237 (87) 0.6 United States 40 (5) 26 (4) 14 (5) 0.5 Married 1343 (93) 947 (94) 396 (91) 0.2 Education Less than Bachelorʼs 52 (4) 21 (<1) 31 (7) <0.05 Bachelorʼs 326 (23) 175 (17) 151 (35) <0.05 Graduate/Masterʼs 932 (65) 707 (70) 225 (52) <0.05 PhD/post-grad 132 (9) 106 (11) 25 (6) <0.05 Behaviors Current smoking 54 (4) 49 (5) 5 (1) <0.05 Former smoking 187 (13) 177 (17) 10 (2) <0.05 Family history of CVD Parent 811 (56) 560 (55) 251 (58) 0.3 Sibling (n = 678) 274 (40) 181 (39) 93 (43) 0.5 Regional data among Indians Region % Northern 22% Southern 40% Eastern 5% Western 27% Central 3% (E Flowers, in press, 2010) 32
9 Characteristics Mean ± SD or n (%) Men (n = 1012) Women (n = 433) p-value Age (years) Clinical variables TC (mg/dl) 43 ± ± ± ± ± ± <0.05 LDL (mg/dl) 116 ± ± ± 29 <0.05 HDL (mg/dl) 45 ±12 42 ± ± 13 <0.05 TG (mg/dl) 144 ± ± ± 63 <0.05 Glucose (mg/dl) 90 ± ± ± 12 <0.05 Systolic blood pressure (mmhg) 118 ± ± ± 17 <0.05 Diastolic blood pressure (mmhg) 76 ± ± ± 11 <0.05 BMI (kg/m 2 ) 25.7 ± ± ± Waist circumference (cm) 88 ± ± ± 12 <0.05 Metabolic syndrome 387 (27) 315 (31) 72 (17) <0.05 Gender differences (for women compared to men) Characteristic Unadjusted OR (95% CI) Adjusted* OR (95% CI) TC > 200mg/dl 0.6 (0.5, 0.8) 0.7 (0.5, 0.9) LDL > 160mg/dl 0.4 (0.2, 0.6) 0.4 (0.2, 0.6) HDL < 40mg/dl (men) < 50mg/dl (women) 1.1 (0.9, 1.3) 1.0 (0.8, 1.3) TG > 200mg/dl 0.3 (0.2, 0.4) 0.3 (0.2, 0.4) Glucose > 126 mg/dl 0.3 (0.1, 0.8) 0.3 (0.1, 0.7) Blood pressure > 140/ (0.3, 0.7) 0.5 (0.4, 0.8) BMI > (0.6, 0.9) 0.8 (0.6, 1.0) WC > 90cm (men) >80cm (women) 1.2 (0.9, 1.5) 1.3 (1.0, 1.6) *adjusted for age, smoking, and education level (E Flowers, in press, 2010) (E Flowers, in press, 2010) Relationship of HDL and HDL2b (n=798; from 2008) Clinical characteristics HDL 2b: > 20% desirable; < 10%: high risk; Only 77% of variability of HDL-2b is explained by HDL-C 44 of 216 had low HDL2b with normal HDL 1, HDL may be normal despite impaired reverse cholesterol transport 2. HDL-2b may add prognostic value, especially in borderline or low-normal HDL 35 (E Flowers, in press, 2010)
10 Framingham risk factors Metabolic syndrome: # criteria (ATP III) Framingham Offspring Study Asian Indians 39% 26% 17% Men 27% 27% 28% Women 28% 26% 21% 17% p < between sexes Waist > 40 M. 35 F HDL! 40M, 45F Hypertension TG " 150 Glu " % 5 6% 5% 0 Smoking HTN LDL > 160 TG > 250 (Enas, Indian Heart J, 1996) 0% # of metabolic risk factors 1% 0% Metabolic Syndrome Phenotypes n(%) Men Women p-value* n = 854 n = 589 n = 265 WC only 212 (25) 106 (18) 106 (40) <0.003 WC + HTN 63 (7) 47 (8) 16 (6) 0.3 Metabolic Syndrome Prevalence WC + HDL 102 (12) 59 (10) 43 (16) <0.003 WC + TG 65 (8) 47 (8) 18 (7) 0.5 WC + glu 30 (4) 19 (3) 11 (4) 0.5 WC + HTN + HDL 37 (4) 27 (5) 10 (4) 0.6 WC + HTN + TG 28 (3) 23 (4) 5 (2) 0.1 WC + HTN + glu 19 (2) 15 (3) 4 (2) 0.3 WC + HDL + TG 137 (16) 111 (19) 26 (10) <0.003 WC + HDL + glu 15 (2) 10 (2) 5 (2) 0.8 WC + TG + glu 22 (3) 16 (3) 6 (2) 0.7 WC + HTN + HDL + TG 55 (6) 46 (8) 9 (3) 0.02 WC + HTN + HDL + glu 10 (1) 9 (2) 1 (<1) 0.1 WC + HTN + TG + glu 13 (2) 12 (2) 1 (<1) 0.07 WC + HDL + TG + glu 22 (3) 20 (3) 2 (1) 0.02 WC + HTN + HDL +TG + glu 24 (3) 22 (4) 2 (1) 0.02 *Bonferroni corrected p-value for 16 comparisons is *Population based sample **Convenience sample
11 Summary! High prevalence of metabolic syndrome (31%M, 17%F)! Very high prevalence of increased waist circumference based on IDF/WHO cutpoints (58%M, 62%F)! Prevalence of high TG much higher in men (23%M, 8%F)! Only 13% with elevated fasting glucose! HTN not as prevalent (16%M, 9%F)! Most common MetS phenotype was high WC + low HDL + high TG! Obesity, dyslipidemia markedly out of proportion to measurable insulin resistance What about young South Asians? (When does it start?)! Of 2096 participants, 678 were below age 40 at time of screening 41 NCEP/ATP III MetS Components in SAHC cohort, age < 40 Component Total Men Women Low HDL (<40 for women,<50 for men) 48.8% 47.9% 51.0% High Triglycerides (>150 mg/dl) 36.1% 46.6% 11.4% High Systolic BP (> 130mm Hg) 18.1% 20.7% 16.1% High Diastolic BP (>85 mm Hg) 16.1% 20.7% 5.5% High Waist Circumference (>102 cm for men and >88cm for women) High glucose 11.2% 10.1% 13.9% (>110mg/dL) 3.24% 3.99% 1.49% Prevalence of # of Components of Metabolic Syndrome (NCEP) Number Total Men Women % 26.7% 43.0% % 27.9% 30.5% % 28.8% 15.5% 3 9.4% 12.2% 2.6% 4 3.4% 4.0% 2.1% 5 0.3% 0.4% 0% Metabolic Syndrome: 13.1% of population; 16.6% of men and 4.7% of women
12 IDF MetS Components in SAHC cohort, age < 40 Total Men Women High Waist Circumference +0 risk factors High Waist Circumference + 1 risk factor High Waist Circumference +2 risk factors High Waist Circumference + 3 risk factors High Waist Circumference +4 risk factors 31.0% 26.1% 42.6% 34.7% 30.7% 44.1% 24.5% 30.5% 10.4% 8.11% 10.5% 2.5% 1.78% 2.3% 0.50% Prevalence of Metabolic Syndrome: 34.4% of population, 43.3% of men, 13.4% of women Lp(a) -2-3 x greater risk of MI -Primarily genetic -Associated with cardiovascular disease inhibit fibrinolysis increase LDL oxidation increase deposition of cholesterol -Lp(a) > 20 mg/dl considered abnormal Average Total Men Women Lp(a) (mg/dl) Total Men Women Lp(a) >20 mg/dl43.4% 41.0% 50.0% Relationship of metabolic syndrome to dyslipidemia # MetS criteria p = Total Chol LDL LDL iiia+b (%) HDL LDL:HDL HDL2B (%) TGs NS NS < < < NS Relationship of metabolic syndrome to inflammatory and thrombotic biomarkers # MetS Criteria Lp(a) Homocysteine CRP Fibrinogen Adjusting for statin, niacin, folate, and B12 therapy, mean Lp(a) fell 3.39 mg/dl for each extra component of MetS, while mean homocysteine and CRP rose 0.35 umol/ml and 0.24 mg/l, respectively (for all, p < for trend). (Divakaruni M, accepted for ACC 2010) 47 48
13 Conclusions! In this cohort of young- and middle-aged South Asian participants presenting for screening:! Large burden of traditional risk factors present at an early age! Consistent with Interheart (Yusuf et al), Atlanta & SHARE (Canada) studies! Occurs despite higher educational status and higher rates of private insurance and access to care! Abnormal waist circumference, LDL, HDL across all age ranges. Affected younger patients are more likely male! High prevalence of metabolic syndrome components without hyperglycemia Risk stratification and treatment of the Bay Area South Asian population is an unmet clinical need 49 Recommendations! Role of generalized advanced lipid and biomarker screening is controversial in all patients, including South Asians! South Asians adults, even age 20-40, should have a waist circumference, lipid panel, and blood pressure performed! Exercise, caloric restriction, weight loss! Lp(a) may be a useful adjunct, but prognosis and management of isolated elevated Lp(a) is unclear It s in the genes... Polymorphisms uniquely associated with CAD in South Asians:! Beta-fibrinogen (455GA, 148CT)! Factor VII (10bp promotor, R353Q; protective?)! ATP-binding cassette transporter (237indelG; 8994AG)! Platelet glycoprotein IIIa (A2 variant)! Apolipoprotein E (E3/E4 genotype)! Thrombomodulin (Ala455Val in smokers)! Endothelial nitric oxide synthase (Glu298Asp)! Tumor necrosis factor 2 (MM variant)! PECAM-1 (Leu125Val)! Cardiomyopathy (not CAD): Protein myosin binding chain PMBC3 (Nature Genetics, 2009) 51 52
14 Telomere shortening occurs in Asian Indian Type 2 diabetic patients. Adaikalakoteswari A, Balasubramanyam M, Mohan V. METHODS: Measure of average telomere size, in leucocyte DNA. Type 2 diabetic patients without any diabetes-related complications (n = 40) and age- and sex-matched control nondiabetic subjects (n = 40) were selected from the Chennai Urban Rural Epidemiology Study (CURES). RESULTS: Mean (+/- SE) TRF lengths of the Type 2 diabetic patients (6.01 +/- 0.2 kb) were significantly shorter than those of the control subjects (9.11 +/- 0.6 kb) (P = ). Among the biochemical parameters, only levels of TBARS showed a negative correlation with shortened telomeres in the diabetic subjects (r = -0.36; P = 0.02). However, telomere lengths were negatively correlated with insulin resistance (HOMA-IR) (r = -0.4; P = 0.01) and age (r = -0.3; P = 0.058) and positively correlated with HDL levels (r = 0.4; P = 0.01) in the control subjects. Multiple linear regression (MLR) analysis revealed diabetes to be significantly (P < ) associated with shortening of TRF lengths. Thank you CONCLUSIONS: Telomere shortening occurs in Asian Indian Type 2 diabetic patients. Diabet Med Sep;22(9):
The Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationMethods. OR and PAR both presented with 99% confidence intervals. All analyses adjusted for age, sex and region.
INTERHEART: Aims 1. To evaluate the association (odds ratio) of risk factors for MI globally, and in each region; and among major ethnic groups in the world. 2. To quantify the impact of each risk factor
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationFigure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None BURDEN OF CORONARY ARTERY DISEASE IN DIABETES IN INDIA Amal Kumar Banerjee MD, DM,FACC,FESC,FACP,FAPSC,FICC President Association of Physicians of India SAARC Cardiac
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationASSeSSing the risk of fatal cardiovascular disease
ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationPrediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal
Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal Koju R, Gurung R, Pant P, Humagain S, Yogol CM, Koju A, Manandhar K, Karmacharya B, Bedi TRS Address for Correspondence:
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationPrevalence of Cardiac Risk Factors among People Attending an Exhibition
IOSR Journal of Nursing and Health Science (IOSR-JNHS) e-issn: 2320 1959.p- ISSN: 2320 1940 Volume 3, Issue 6 Ver. IV (Nov.-Dec. 2014), PP 4-51 Prevalence of Cardiac Risk Factors among People Attending
More informationCardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010
Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010 CAVEAT LECTOR 2 CVD-related Mortality in Aging SCI GU
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationWomen s Heart Health: Risk, Diagnosis and Management Differences MANAGEMENT
Women s Heart Health: Risk, Diagnosis and Management Differences MANAGEMENT C. Noel Bairey Merz MD Medical Director and Barbra Streisand Women s Heart Center Preventive Cardiac Center Cedars-Sinai Heart
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationMetabolic Syndrome in Asians
Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationRoadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total
Diabetes and the Metabolic Syndrome in the Asian Population Alka Kanaya, MD Associate Professor of Medicine, UCSF Feb 26, 2010 Roadmap 1. Diabetes in Asian Americans Prevalence in the U.S. Risk factors
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationPOST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) Term-End Examination June, 2015
No. of Printed Pages : 20 MCC-006 POST GRADUATE DIPLOMA IN CLINICAL 0 CARDIOLOGY (PGDCC) Term-End Examination June, 2015 MCC-006 : CARDIO VASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note :
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationWomen and Heart Disease
Women and Heart Disease The Very Latest in Cardiovascular Medicine and Surgery Gretchen L. Wells, MD, PhD, FACC Thomas Whayne Endowed Professor in Women s Heart Health Gill Heart Institute University of
More informationCase Presentation. Moderator: Sharon Liu, DO Associate Internal Medicine Chief Austin Regional Clinic Austin, Texas
Case Presentation Moderator: Sharon Liu, DO Associate Internal Medicine Chief Austin Regional Clinic Austin, Texas Izzy (2006) 51 y/o Hispanic woman with a history of diabetes and obesity. Her diabetes
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationThe Gender Divide Women, Men and Heart Disease February 2017
The Gender Divide Women, Men and Heart Disease February 2017 Nandita S. Scott, MD FACC Co-Director MGH Heart Center Corrigan Women s Heart Health Program Massachusetts General Hospital Heart Disease For
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationMetabolic Syndrome: A Preventable & Treatable Cluster of Conditions
Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions April D. McNeill MD Candidate 2016, Southern Illinois University, School of Medicine GE-NMF Primary Care Leadership Program, July 2013
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationKEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
More informationLipid Markers. Independent Risk Factors. Insulin Resistance Score by Lipid Fractionation
Patient: SAMPLE PATIENT DOB: Sex: MRN: 3701 CV Health Plus Genomics - Plasma, Serum & Buccal Swab Methodology: Chemiluminescent, Enzymatic, Immunoturbidimetric, NMR and PCR Lipid Markers Cholesterol LDL-
More informationDIABETES. A growing problem
DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought
More informationLipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures
Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationHeart Disease Genesis
Heart Disease Genesis The Ultimate Lecture on CAD origins Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More information5/28/2010. Pre Test Question
Myth of Metabolic Syndrome? C. W. Spellman, DO, PhD Professor and Associate Dean Research Dir. Center Diabetes and Metabolic Disorders Department Internal Medicine, Div. Endocrinology Texas Tech University
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationMetabolic Syndrome: What s in a name?
Commentary Metabolic Syndrome: What s in a name? Deborah P. Wubben, MD, MPH; Alexandra K. Adams, MD, PhD Abstract The term metabolic syndrome has recently become en vogue. But is the definition realistic,
More informationCardiovascular Risk Assessment and Management Making a Difference
Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014 Numbers and age-standardised mortality rates from all causes, by sex, 1950 2010 Death rates halved Life expectancy
More information7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)
University Pharmacy 5254 Anthony Wayne Drive Detroit, MI 48202 (313) 831-2008 Be able to identify the signs of a heart attack or stoke Identify what puts you at a higher risk for cardiovascular disease,
More informationEpidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl
Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationNon communicable Diseases
Non communicable Diseases Vision, Goals and Challenges Where we are in Palestine? Dr. Johny R. Khoury Consultant Cardiologist Medical Relief Prevention and Diagnostic Center of cardiovascular diseases
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationMyths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population!
Myths, Heart Disease and the Latino Population Maria T. Vivaldi MD MGH Women s Heart Health Program Hispanics constitute 16.3 % of US population! 1 LEADING CAUSES OF DEATH IN LATINOS Heart disease is the
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationWeintraub, W et al NEJM March Khot, UN et al, JAMA 2003
Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine
More informationLow HDL-levels: leave it or treat it?
Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960
More informationPatient: Shawn Baker March 06, 2018
Mr. Shawn Baker Dear Participant: Our team at SpecialtyHealth has received your lab work and the results have been reviewed. In this letter you will find a summary of the results along with numerous charts
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationKnow Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationNOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet
NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet FASTING 16 hours a day EXCERCISE 150 min a week DIET Low carb NOSM Northern Research Conference, Kenora, 2018 R Minty, T O Driscoll, L Kelly,
More informationCardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh
"Insight Heart" is also available at www.squarepharma.com.bd Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh Coronary heart disease has been emerging as an
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More information